Most Recent Annual Report
2019 Annual Report and Form 10K

Five Prime Therapeutics Inc has reached its limit for free report views.
You can request a free hardcopy of this report mailed to you by clicking the button below.
Five Prime Therapeutics Inc has reached its limit for free report views.
You can request a free hardcopy of this report mailed to you by clicking the button below.
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ib clinical trials for the treatment of rheumatoid arthritis; and in pre-IND stage for pigmented villonodular synovitis and multiple cancers in combination with nivolumab.